The corporate had been doing both for four years. A EUR 50 million internal innovation fund, run by a team of four, tasked with identifying and building new products from within the business. A EUR 40 million CVC vehicle, run by a separate team of three, tasked with identifying early-stage companies with strategic relevance to the parent.
By year three, both programmes had a problem. The internal innovation fund was being reviewed against financial return targets it had not been designed to hit, because the board had begun using the same IRR benchmarking framework for both vehicles at the same time. The CVC team was being required to seek internal business unit approval before making investment decisions, because the corporate development function had begun treating CVC investments as pre-acquisition candidates rather than minority positions providing option value. Three deals were lost in the time spent on internal approval processes. Two companies that had gone through the internal innovation programme were eventually killed because they could not hit revenue milestones that were appropriate for a commercial business unit but not for a five-person team with an eighteen-month runway.
Neither team was failing at what it was originally designed to do. Both were failing at what the organisation had, over time, decided it should be doing. The governance design had not kept pace with the resource allocation. The budgets had merged in the board’s perception even when they were legally separate. The metrics had converged into a single ROI framework that was inappropriate for either activity.
The strategic choice between investing in internal innovation and acquiring external venture exposure is one of the most consequential decisions a large EU corporate makes in its technology strategy. Most EU corporates get both wrong because they blur the distinction: they invest in both without designing either for its specific purpose.
The Structural Difference, a Decision Framework, and the Three Most Common Mistakes
The structural difference between internal innovation investment and external venture exposure
These two activities have different objectives, different time horizons, different team profiles, different success metrics, and different governance requirements. Managing them as a single budget line or holding them to the same performance framework systematically degrades the quality of both.
Internal innovation investment is essentially a research and development activity with a commercialisation horizon. Its objective is to generate proprietary knowledge, build capabilities, or develop products that the parent organisation cannot buy from a vendor or access through a minority investment. It requires teams with the operating discipline to build within a corporate context, which means navigating procurement, legal, and human resources processes that an independent startup does not face. Its time horizon is typically five to eight years from concept to material commercial contribution. Its success metrics should be capability-based at the first stage: what does this organisation know now that it did not know before, and what option value has been created? Financial return metrics are appropriate only after the product or capability has been commercialised. Applying financial return metrics to an internal innovation programme in its first two years is the equivalent of asking a research scientist to show a profit on the experiment before the experiment is complete.
External venture exposure, through a CVC mandate or LP commitment in a specialist fund, is a strategic option-creation activity. Research on CVC strategic objectives identifies three clusters: strengthening the core business, leveraging the ecosystem, and exploring new markets and technologies. The literature is clear that which objectives can be simultaneously pursued depends on the structural integration and autonomy of the CVC unit. A CVC investment does not build the corporate’s own capability. It purchases access to information, to a sector’s development trajectory, and to the option to acquire, partner, or pilot with the portfolio company at a later stage. Its success metrics are not the IRR of the investment in isolation. They are the quality of market intelligence produced, the number of pilots initiated, and the strategic relevance of the acquisition pipeline maintained.
Measuring CVC success requires metrics beyond traditional venture IRR, including technology adoption rate, market access acceleration, and competitive intelligence value, alongside conventional financial metrics. A corporate that reports CVC performance using portfolio IRR alone is measuring a partial signal. The strategic return, the information asymmetry purchased, the option value created, and the M&A pipeline de-risked, is typically larger in value and harder to quantify.
A decision framework: build, partner, buy, invest
| Mode | Objective | When Appropriate | What It Requires | What It Cannot Do |
| Build (internal innovation) | Develop proprietary capability or product that cannot be bought or accessed externally | When the capability requires deep integration with the corporate’s existing IP, data, or distribution, or when the market does not yet have a venture-backed company worth backing | A dedicated team with operational autonomy from the parent’s quarterly review cycles; milestone-based governance designed for early-stage development; 5–8 year horizon | Move at startup speed; access external talent markets on competitive terms; scale independently of the parent’s existing business constraints |
| Partner (accelerator sponsorship, co-development, pilot programme) | Generate early access to emerging companies, test integration feasibility, and build relationships without equity commitment | When the corporate needs market intelligence across a sector and cannot identify a specific company worth backing, or when the internal team lacks the bandwidth to manage equity investments | A defined business unit owner for each partnership with specific KPIs (pilots initiated, technologies evaluated, hires made from programme alumni); governance separate from CVC mandate | Create proprietary position; prevent strategic competitor from backing the same company; convert to acquisition without a separate transaction process |
| Buy (acquisition) | Acquire proven capability, team, technology, or market position | When the capability is sufficiently mature that the build cost exceeds the acquisition cost, and when the integration risk is manageable | Corporate development capacity for deal structuring and post-acquisition integration; clear strategic rationale; integration plan approved before close | Provide option value across early-stage adjacencies; allow the acquired team to operate with startup speed post-close without specific integration design |
| Invest (CVC direct or LP commitment) | Purchase strategic option value, market intelligence, and early access to acquisition candidates | When the sector is developing faster than the internal team can track; when the corporate wants minority exposure to multiple companies across a thesis area; when acquisition is possible but not certain | Investment team with genuine autonomy from parent approval processes; governance framework that separates investment decisions from commercial relationship decisions; strategic return metrics defined before first deployment | Build the corporate’s own capability; guarantee access to the portfolio company’s IP or team through the minority position alone |
EU automotive companies’ CVC investment provides an instructive case: the top five EU automotive firms direct a larger proportion of their CVC investment to US-based startups than to domestic ones, primarily in high-risk transformative technologies such as autonomous driving and sensor systems. This pattern illustrates the appropriate use of CVC: to access innovation in adjacent and emerging areas that internal teams cannot build fast enough, regardless of geography, rather than to reinforce the core business that internal development can address.
The three most common EU corporate innovation investment mistakes
Underfunding internal teams. The most common failure mode for internal corporate innovation programmes is not technical; it is structural. A team of four people with an EUR 8 million annual budget operating within a corporate governance framework designed for a EUR 500 million business unit does not have the operational autonomy or resource density to compete with a well-funded startup. The team typically spends a disproportionate proportion of its time on internal approvals, procurement processes, and quarterly reporting rather than on the actual work of building. This produces programmes that run for three or four years, consume substantial budget, and generate very little commercial output, not because the idea was wrong but because the operational context was wrong. The fix is not more money. It is a governance structure that separates the innovation team’s operations from the parent’s standard processes on a defined list of decisions, with specific autonomy parameters agreed before the programme begins.
Over-governing CVC mandates. Advisory analysis of CVC in 2025 consistently identifies that strategies which are more deliberate, allow greater independence from the parent, and focus on fewer but better-aligned deals produce stronger outcomes. The pattern that destroys CVC programme value is the requirement for internal business unit approval before investment decisions. This requirement typically develops organically: a business unit leader sees the CVC investment as a pre-acquisition candidate and wants to be consulted. The investment team accommodates the request. The process slows. Two or three deals are lost in the time required for internal approval. The CVC begins to invest in companies that have passed business unit review rather than companies that represent the strongest strategic option value, which are not always the same companies. The governance solution is to separate the investment decision from the commercial relationship decision explicitly and permanently: the CVC team makes investment decisions based on strategic thesis fit, speed, and valuation; the business unit team decides whether to initiate a pilot or commercial relationship with portfolio companies, on its own timeline.
Conflating strategic exposure with financial return. Research examining 473 startups funded by independent and corporate venture capitalists found that CVC-backed startups patent more but are less likely to go public, suggesting that the incentives and capabilities of corporate investors leave a strong imprinting effect on portfolio companies’ long-term outcomes. When a corporate CVC is evaluated on portfolio IRR against independent VC benchmarks, it is being evaluated on a metric it was not designed to optimise. The consequence is that investment decisions shift toward companies with shorter paths to financial exit and away from the early-stage, strategically adjacent companies where the CVC’s actual comparative advantage, its sector knowledge, distribution access, and co-development potential, is most valuable. The measurement framework corrects the incentive structure.
The Implication
The EU corporate innovation underperformance problem is a governance design problem, not an ambition problem. The EU Competitiveness Compass, adopted in January 2025 as the Commission’s primary policy response to the Draghi report, identifies closing the innovation gap as its first imperative, noting that the EU corporate R&D system has materially weaker creative-destruction capacity than the US or China. The analysis correctly identifies the structural problem. The governance solution sits at the level of the individual corporate, not the policy framework.
The corporates that generate durable strategic value from their innovation investment are the ones that make two decisions explicitly before any capital is committed: which of the four modes is appropriate for this objective, and what governance structure, autonomy parameters, and success metrics are designed specifically for that mode? These are not strategic questions. They are operational design questions. They are answered in internal policy documents, budget structures, and governance frameworks rather than in market-facing announcements.
The strategic ambition is present in most large EU corporates. The governance design to support it is the constraint. Resolving the constraint does not require regulatory change or additional capital. It requires the discipline to manage build, partner, buy, and invest as genuinely different activities with different mandates rather than variations on the same innovation budget line.